Treprostinil
Treprostinil 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Pulmonary Hypertension。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
19 项
全球在招研究
10 项
已进入 III/IV 期
32 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Valley Health System
- Insmed Incorporated
- Ferrer Internacional S.A.
- Bastiaan Driehuys
- Hospices Civils de Lyon
- Liquidia Technologies, Inc.
- United Therapeutics
- Pulmovant, Inc.
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Argentina、澳大利亚、奥地利、比利时、Brazil、Colombia、Czechia、丹麦、法国、Georgia、德国
正在招募患者的 Treprostinil 研究
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
III 期招募中美国Argentina澳大利亚奥地利NCT07179380Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and Effectiveness
不适用招募中法国NCT06499363Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia
II 期招募中美国NCT07037836Exploration of Metabolome in Patients With Interstitial Lung Disease and Pulmonary Hypertension With or Without Specific Pulmonary Hypertension Treatment
不适用招募中法国NCT07254338A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
IV 期招募中美国NCT07759804Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
III 期招募中美国Argentina澳大利亚比利时NCT05943535A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
II 期招募中美国NCT07333183A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
I 期招募中美国NCT07643155COMPERA / COMPERA-KIDS
不适用招募中比利时德国意大利瑞士NCT01347216DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
不适用招募中美国Puerto RicoNCT06388421Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH
III 期招募中奥地利法国HungarySlovakiaNCT06350032Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation
I 期 / II 期招募中美国NCT04005469An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
III 期招募中美国Czechia法国GeorgiaNCT07234032Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)
早期 I 期招募中美国NCT07837830A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
III 期招募中美国澳大利亚奥地利比利时NCT07285655Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
III 期招募中美国NCT04062565A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
III 期招募中美国Argentina澳大利亚IsraelNCT07481981Open Label Treprostinil Raynaud's Study
IV 期招募中美国NCT07112183Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients
IV 期招募中Argentina奥地利Czechia法国NCT06317805
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。